HCM
BIIB icon

Highline Capital Management’s Biogen BIIB Stock Holding History

Highline Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-243,700
Closed -$69.1M – 45
2016
Q4 		$69.1M Hold
243,700
– – 1.97% 25
2016
Q3 		$76.3M Buy
+243,700
New +$72.2M 2.59% 17

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Highline Capital Management's BIIB Position: Q2 2018 in Review

Highline Capital Management sold out of Biogen (BIIB) in Q2 2018, closing a stake of 361,450 shares — an estimated $99M sold.

Highline Capital Management first reported a position in BIIB in Q1 2015 and held it in 5 quarters. The position peaked at $99M in Q1 2018. 1,097 funds tracked by Wall St. Rank hold BIIB as of Q2 2018.

  • Highline Capital Management reported no remaining Biogen position as of Q2 2018 after selling out during the quarter.
  • Highline Capital Management sold 361,450 Biogen shares in Q2 2018, an estimated $99M.
  • Highline Capital Management first reported a position in Biogen in Q1 2015 and held it in 5 quarters.
  • Highline Capital Management's Biogen position peaked at $99M in Q1 2018.
  • 1,097 funds tracked by Wall St. Rank held Biogen as of Q2 2018.

Based on Highline Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.